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It is uncommon to find published clinical trials that measure the health benefits of 
medical testing. As a consequence, policy makers often have to decide whether 
access to, or public funding of, medical tests is warranted without knowing the 
clinical impact of testing on the patient. In the situation where a policy maker is 
considering a companion genetic test and tailored drug therapy, deficiencies in the 
evidence base are exacerbated because two technologies need to be assessed and the 
proposed genetic biomarker needs to be validated. The Linked Evidence Approach 
(LEA) is a methodology that was developed in 2005 to cope with inadequacies in the 
evidence supporting medical test evaluations. In 2010 the approach was adapted to 
the evaluation of pharmacogenetic interventions. This article describes how LEA and 
similar analytic frameworks are used internationally, highlights particular challenges 
with the approach, and proposes ways that LEA might be applied to pharmacogenomic 
interventions.
Keywords: • biological markers • biomedical • diagnostic test approval • economics • health 
policy • health services accessibility/economics • individualized medicine • molecular targeted 
therapy • outcome assessment (health care)/economics • outcome assessment (health care)/
methods • pharmaceutical • pharmacogenetics • technology assessment
Background
Tests are not perfect
In the past, tests have not received the same 
degree of scrutiny by policy makers, when for-
mulating public funding decisions, as thera-
pies have traditionally received. This could be 
because therapies have immediate and obvi-
ous impacts on patient health, whereas the 
consequences of testing are indirect and not 
immediately observable. However, tests are 
far from perfect and may result in immedi-
ate harm (associated with the procedure), or 
harm secondary to inaccurate information. 
Factors that can affect test accuracy include: 
poor communication and insufficient under-
standing of testing procedures; inappropriate 
test selection/ordering and interpretation of 
results; patient and/or specimen misiden-
tification; inadequate specimen obtained 
for testing; specimen collection errors; and 
specimen contamination [1].
Advances in genetic testing have raised 
further quality challenges. A survey of all 
pathology laboratories in Australia, where 
test regulation and accreditation is fairly 
stringent, reported that genetic tests ranged 
considerably in their ability to correctly iden-
tify patients who have the target condition 
[2]. The estimated analytic sensitivities were 
largely concordant across the 52 laboratories 
surveyed (Table 1) and suggest that, in the 
most extreme example, up to 80% of patients 
with a condition could receive a false negative 
test result.
Even a small amount of imperfection 
in test accuracy can undermine the com-
mercial viability and cost-effectiveness of a 
companion diagnostic and therapy [3]. For 
example, if a test has a high false positive 
rate, more patients would receive an inap-
propriate treatment resulting in an increase 
in treatment costs for no additional health 
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gain. The test/therapy combination would not be cost-
effective and unlikely to receive government or insur-
ance subsidization. The impact of test performance on 
the cost-effectiveness of therapies might have spurred 
the introduction of methods guidance in the UK [4,5], 
Europe [6] and the USA [7–9] (2008–2012) regarding 
the evaluation of tests for regulation and reimburse-
ment purposes. Australia – perhaps because it had a 
policy mechanism specific to the evaluation of tests as 
part of a medical service – produced its guidance on 
medical test evaluation for reimbursement purposes in 
2005 [10].
Evaluation of tests, when performed, is often 
restricted to test performance only (sensitivity, specific-
ity etc) with little consideration given to the impact on 
patients of receiving a false negative result – leading to 
delayed treatment – or of a false positive result – lead-
ing to inappropriate treatment (no additional clinical 
benefit and additional harms from toxicity) [11]. This, 
in part, may be because many geneticists and labora-
tory scientists believe that the information from testing 
has value in and of itself [12]. However, it may also be 
due to the lack of direct trial evidence assessing the 
impact of testing on patient health outcomes.
Di Ruffano et al. (2012) conducted a capture-recap-
ture analysis using two searches (broad and specific) 
from the Cochrane CENTRAL hand searched trial 
database to estimate the number of randomised con-
trolled trials published on diagnostic tests between 
2004–2007. Of the 23,888 randomized controlled 
trials retrieved, 135 were found to be diagnostic ran-
domised controlled trials. The capture-recapture anal-
ysis estimated 37 diagnostic trials were published per 
year for the 4 years [13]. This is in contrast with the 
5938 therapeutic trials per year that were known to 
have been published.
In general, if a test performs poorly in a diagnos-
tic effectiveness trial, false positive and false negative 
test results will be reflected in the measured health 
outcomes of patients. However, as trial evidence of 
the impact of medical, including genetic, tests on the 
health outcomes of patients is often scarce, policy mak-
ers are faced with making decisions on access to, and 
reimbursement of, tests on the basis of incomplete and 
uncertain information.
The ‘Linked Evidence Approach’ (LEA)
To address this evidence gap, in 2005 a methodology 
was published that aimed to provide the maximum 
amount of information on test effectiveness and cost–
effectiveness to Australian policy makers [10,14]. This 
‘linked evidence approach’ (LEA) involves the narra-
tive linking of evidence assessing components of a test-
treatment pathway in order to predict the likely impact 
of testing on patient health outcomes. The method 
was informed by criteria developed by Fryback and 
Thornbury (1991) to assess the efficacy of diagnostic 
imaging tests [15]. These criteria include technical effi-
cacy, diagnostic accuracy, diagnostic thinking (change 
in diagnosis), therapeutic efficacy (change in manage-
ment) and patient outcome efficacy (change in health 
outcomes). The method was also informed by analytic 
frameworks pioneered by the US Preventive Services 
Task Force (USPSTF) to identify key questions that 
Table 1. Range of genetic test methods offered by 52 Australian laboratories and their estimated 
analytic sensitivity†.
Method No. of types of tests 
based on method 
No. of 
reports
Range of expected 
analytic sensitivity
No. of discordant 
reports‡ 
Diagnostic genetic tests (mutation identification)
Mutation screening 48 48 60% to >94% nil
Sequencing 146 174 20% to >94% 4
Sequencing plus MLPA 51 101 60% to >94% 2
Specific assays 108 177 <20% to >94% 2
FISH 25 47 60% to >94% 1
Somatic testing
Mutation screening 2 2 80% to >94% nil
Sequencing 3 3 80% to >94% nil
Specific assays 29 66 40% to >94% 8
FISH 32 51 >94% nil
† Data taken with permission from [2].
‡Expected analytic sensitivity for the same method and type of test varying by >20% in different laboratories.
FISH: Fluorescent in situ hybridisation; MLPA: Multiplex ligation-dependent probe amplification.
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guide clinical practice guideline development [16]. 
These frameworks address both the harms and benefits 
of medical testing on the patient [17–19].
The Guidelines on LEA [10] recommend the system-
atic review and narrative linking of evidence under cer-
tain conditions. This linking of evidence would occur 
in instances where direct trial evidence of the effect 
of testing on patient health outcomes is not available 
or inadequate for decision making purposes [10]. The 
evidence linkage is primarily undertaken as a method-
ological substitute for the ideal hypothetical trial that 
would be used to measure the health benefits of the test 
on patients (Figure 1) [14]. The trial design is broken 
down into its elements and used as a template for the 
decision analytic model which integrates the informa-
tion and determines whether the new test is both effec-
tive and cost-effective [14]. Evidence addressing each 
element of the decision analytic model is systematically 
acquired and rigorously critiqued.
A systematic literature review of Australian health 
technology assessments (HTAs) [20] reported that the 
method had been applied to 85 patient indications for 
testing between 2005 and 2012. The method was used 
on tests for diagnostic, staging and screening purposes, 
as well as for genetic tests [21,22].
In the original Guidelines on LEA, it was noted that 
if there was evidence that the patients eligible for the 
new test are similar (transferable) to those patients cur-
rently receiving treatment for the condition, the findings 
of test accuracy studies could be considered sufficient to 
determine the clinical utility of the new test [10]. This 
means that the findings from studies that report the 
effect of the comparator (current) test on (i) the selec-
tion of treatment options for patients, and (ii) the flow-
on effects of treatment on the health of these patients, 
could be used in a decision analytic model to simulate or 
predict the health benefits associated with the new test.
A key element of this transferability assumption 
is Fryback and Thornbury’s criterion on change in 
management (see Figure 1). If the test, no matter how 
accurate, does not change the treatment options or 
management offered by the health professional to a 
patient, then there will be no impact of the test on the 
patient’s health status. This means that there is no need 
to evaluate the safety and effectiveness of the treatment 
options in the linked test-treatment pathway. Put sim-
ply, the new test would create an additional cost for no 
additional patient health benefit and so would be con-
sidered cost-ineffective. A decision framework has been 
developed to assist those applying the linked evidence 
approach, including providing guidance on the type 
and extent of evidence needed in a linkage [20].
Staub et al. (2012) reviewed the methods used in 
English-language HTAs of medical tests to assist pol-
icy makers with regulation and reimbursement deci-
sions [11]. The review encompassed the work of 18 
HTA agencies in eight countries and found that 48% 
of the 149 HTAs reported only on test accuracy, 11% 
on test accuracy and the impact of treatment, 24% on 
test accuracy and impact on patient management, and 
17% on all linked evidence elements. Of the 17 HTAs 
reporting the use of an analytic framework, Fryback 
and Thornbury’s criteria was cited as the integrative 
framework in five HTAs, while the Australian linked 
evidence approach was cited in 12 HTAs.
The use of evidence linkage and integrative frame-
works in medical test evaluation, in order to inform 
policy decisions, is increasing and is now recom-
mended by many of the major technology assessment 
organizations internationally [5–7,10,23].
Genetic testing & methods of evaluation
According to a status report published in 2007, approx-
imately 6.8 billion laboratory tests are performed 
annually in the USA [1]. The revenue, spending, and 
test volume of the clinical laboratory testing market 
has grown steadily. More than 4000 laboratory tests 
were available for clinical use in 2007, of which 1162 
tests were reimbursed by US Medicare [1].
A key initiative developed specifically for the evalu-
ation of genetic tests by the Centers for Disease Con-
trol and Prevention in 1997, was the creation of the 
Office of Public Health Genomics which in turn 
sponsored the ACCE Model project in 2000 [12]. The 
ACCE Model was the first publicly-available analyti-
cal process for specifically evaluating scientific evi-
dence on emerging genetic tests. The model presents 
44 questions that need to be addressed to determine 
the Analytic validity, Clinical validity, Clinical util-
ity, and Ethical, legal, social implications (ACCE) of 
a genetic test [8]. It was applied to the assessment of 
several genetic testing technologies, including – in 
the first instance - an assessment of prenatal screening 
for cystic fibrosis via carrier testing for CFTR muta-
tions [24], as well as in mini-reviews of genetic [25] and 
pharmacogenetic tests  [26].
In 2004 the Office of Public Health Genomics estab-
lished the Evaluation of Genomic Applications in Prac-
tice and Prevention (EGAPP) initiative and, in 2005, 
a Working Group was created to develop an evidence-
based process for assessing genetic tests and other 
clinical applications of genomic technology [27]. The 
EGAPP initiative commissions systematic reviews of 
genetic tests that address key questions that have been 
developed using USPSTF-style analytic frameworks, 
as well as using elements of the ACCE model.
The EGAPP Working Group has reported difficul-
ties in generating evidence-based recommendations 
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regarding the clinical utility of different genetic tests 
because of the scarcity of good quality evidence. The 
Working Group speculated that randomized controlled 
trials were lacking because of the constraints imposed 
by time, recruitment and resources when designing 
and implementing studies on testing for rare condi-
tions or when the downstream effects of treatment 
involved relatively small effect sizes compared with 
usual care. The Working Group methods allow for the 
use of observational or nonrandomized evidence when 
high level evidence is not available [12,27].
This is very similar to the Linked Evidence Approach 
whereby different hierarchies of evidence and appro-
priate critical appraisal techniques are used to address 
different types of questions in the linkage [10]. The 
evidence hierarchy that is used addresses questions on 
diagnostic accuracy, interventions (relevant for direct 
evidence of diagnostic effectiveness and change in 
management studies), aetiology, prognosis and screen-
ing. It was originally produced to assist with clinical 
practice guideline development [28].
The synthesis of evidence supplied to the EGAPP 
Working Group is used to formulate recommenda-
tions on the use of genetic and genomic tests in clinical 
practice [29,30]. EGAPP information is disseminated to 
various stakeholders but the EGAPP initiative is not 
directly responsible for the regulation or reimbursement 
of genetic tests [27].
Direct evidence of test effectiveness
Linked evidence of test effectiveness
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Figure 1. Estimating the clinical effectiveness of testing using the linked evidence approach. 
a The results from one or more of these trials (including meta-analyses) would form the direct evidence base 
showing test impact on patient health outcomes. 
b The results from one or more of each of these types of studies and trials (including meta-analyses) would form 
the linked (or indirect) evidence base predicting the test impact on patient health outcomes. 
c Populations, tests and outcome definitions should be transferable (similar) across linkages. 
Adapted from [10].
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Molecular testing has seen recent, rapid and esca-
lating growth in developed economies, especially in 
the fields of infectious diseases and oncology [1,2]. This 
may, in part, be because these tests can identify par-
ticular genetic biomarkers that predict the therapeu-
tic performance of specific drugs (pharmacogenetic 
application). Molecular testing methods identify spe-
cific sequences of human DNA or RNA to identify 
errors (mutations) that may or may not be associated 
with disease ie single nucleotide polymorphism, gene 
insertion, deletion or rearrangement. In Australia, 
requests for molecular tests increased 2.8-times from 
2006 to 2011 [31]. Somatic genetic tests and diagnostic 
(mutation identification) tests each increased by 23% 
from 2006 to 2007, whereas pharmacogenetic tests 
increased by 101% [2]. Pharmacogenetic interventions 
involving a companion genetic test and tailored drug 
treatment have been emerging over the last decade and 
this has created challenges for existing regulation and 
reimbursement technology approval mechanisms.
Practical difficulties with the evaluation of 
pharmacogenetic interventions for policy 
decisions
There are some impediments to the evaluation of 
companion diagnostics and pharmaceuticals for reim-
bursement decisions. Terasawa et al. reported large 
differences in the way genetic factors are grouped and 
analyzed within pharmacogenetic studies, making it 
difficult to combine and interpret findings across stud-
ies [32]. Similarly, Laksman and Detsky (2011) noted 
that “the huge number of genes available for demon-
strated associations and the wealth of information 
being churned out at an increasing pace leave some 
with the feeling that we are producing more data than 
we can analyze or understand” [33].
Perhaps this is the reason why Holmes et al., when 
they conducted a systematic review of pharmacoge-
netic studies in 2009, found that the ratio of com-
mentary/reviews to original research in the available 
evidence base (4674 papers spanning 1967–2007) was 
25:1 [34]. Researchers and clinicians appear to be strug-
gling to process all of the available information into a 
cohesive whole.
Holmes et al. also reported that of the original phar-
macogenetic studies obtained, the majority focused 
on candidate genes rather than genome-wide analysis, 
were of inadequate sample size, provided suboptimal 
capture of genetic variation and were characterized by 
‘significance chasing’ and reporting bias [34]. These 
problems lead to a failure to replicate and validate 
genetic associations [35,36].
Similarly, systematic literature reviews on selected 
pharmacogenetic tests for cancer treatment found prob-
lems with the evidence-base on CYP2D6 for tamoxifen 
in breast cancer, KRAS for anti-EGFR antibodies in 
colorectal cancer, and BCR-ABL1 for tyrosine kinase 
inhibitors in chronic myeloid leukemia [32]. Studies had 
small sample sizes and so could not reliably identify 
small treatment effects. Additional problems that were 
observed, irrespective of whether the genetic biomarker 
was a germline polymorphism (CYP2D6) or a somatic 
mutation (KRAS, BCR-ABL), included the lack of for-
mal assessment for treatment-by-biomarker interac-
tions (i.e., treatment effect modification) and the use 
of surrogate short term outcomes of treatment failure 
rather than patient-relevant outcomes such as overall 
survival or progression-free survival. Terasawa  et al. 
noted that adjustments for potential confounding fac-
tors were often not based on sound epidemiological 
principles and that adjustments for multiple compari-
sons were often not documented. The other limiting 
factor in the evidence base was that multiple studies on 
each topic frequently originated from a limited number 
of specialized centers, meaning that populations could 
overlap and potentially threaten the generalizability of 
the findings [32].
There have been recent attempts to strengthen phar-
macogenetic research, including conducting post hoc 
analyses of completed drug trials by genotyping pro-
spectively banked tissue samples from patients prior to 
them being allocated to a treatment arm. Genotyping 
of tissue can be performed after the trial has ended, 
although the benefit of randomization in balanc-
ing confounding variables between trial arms is lost. 
An example of this approach is the pharmacogenetic 
KRAS and CYP2D6 trials [37–39].
Despite some recent improvements in trial design, 
the overall evidence base available to inform policy 
makers on the safety, effectiveness and cost-effec-
tiveness of pharmacogenetic interventions is poor, 
piecemeal and problematic to evaluate and synthesize.
Adapting LEA to pharmacogenetic 
interventions
Meckley and Neumann (2010) analyzed reimburse-
ment decisions from NICE, AETNA, CIGNA, Pre-
mera (Blue Cross), and Centers for Medicare and 
Medicaid Services with regard to six case studies 
– namely, HER2/neu and trastuzumab; hepatitis C 
genotyping and ribavirin/pegylated interferon; Onco-
type DX and chemotherapy; UGT1A1 and irinote-
can; VKORC1/CYP2C9 and warfarin; BRCA1/2 with 
prophylactic surgical measures; and OncotypeDX 
with chemotherapy. The authors observed that the 
strength of evidence available to support the clinical 
benefits/harms of use of a personalized medicine was 
the key determinant in predicting positive reimburse-
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ment decisions [40]. Similarly, Faulkner et al. (2012) 
suggested that efforts to develop a coherent system of 
evaluation of medicines targeted to patients with spe-
cific genetic biomarkers have been hampered by the 
available evidence base which does not fit the estab-
lished approaches to test and drug evaluation for reim-
bursement decisions [41]. This was a problem encoun-
tered by Terasawa et al. in their systematic reviews 
of selected pharmacogenetic tests [32]. The lack of a 
conceptual framework for integrating the disparate 
pieces of evidence meant that there were difficulties in 
developing a coherent picture from the mix of genetic 
association studies, predictive accuracy studies and 
trials showing treatment effects in patients with a bio-
marker. It would also be difficult to determine what 
key evidence, if any, was missing.
Evidence on companion tests and drugs presented for 
reimbursement decisions have typically concentrated on 
assessing the clinical benefit of the drug in patients with 
a particular genetic characteristic, with little attention 
being paid to: (1) whether the proposed test or com-
bination of tests is accurate at identifying that specific 
genetic biomarker, or (2) isolating whether that particu-
lar genetic biomarker is the target (or effect modifier) 
for the drug, as opposed to being a consequence of other 
characteristics that may be defining or responsible for 
that particular patient group responding to the therapy. 
These other characteristics include determining whether 
the genetic biomarker is simply a prognostic factor that 
predicts improved patient health outcomes irrespec-
tive of the treatment offered, or whether the observed 
effect is due to measured (or unmeasured) confounding 
factors introduced through a non-randomized (or non-
stratified) comparison by biomarker status.
In an attempt to address the deficiencies in the avail-
able evidence base for pharmacogenetic interventions 
and to provide a conceptual framework to incorpo-
rate the disparate pieces of evidence, we adapted the 
linked evidence approach used for test evaluation to 
personalized medicines [42]. The aim was to develop 
an approach that was flexible and adaptable to the 
different types of evidence generated in the research 
community and yet still provide robust evaluations of 
the safety, effectiveness and cost–effectiveness of both 
test and drug. Another key aim was to make areas of 
clinical risk and cost uncertainty transparent to policy 
makers.
The co-dependent technology evaluation 
framework
The framework for assessing pharmacogenetic inter-
ventions in Australia has been reported elsewhere 
[42]. In summary, the approach uses the hypothetical 
framework of a double randomized controlled trial as 
a template for determining what information elements 
are needed when linking evidence – this trial design 
is unlikely in practice but consists of all the elements 
needed to evaluate the test, drug and the interaction 
between the two. The use of a hypothetical frame-
work had been suggested previously for undertak-
ing test evaluations in LEA [14]. Consistent with this, 
our framework was informed by an awareness of the 
importance of maintaining transferability across evi-
dence linkages and a need to define the likely biases if 
the transferability assumptions could not be fulfilled. 
Complementary to this approach, given the largely 
observational evidence base associated with pharmaco-
genetic interventions, elements suggested by Bradford-
-Hill to determine causation [43] were incorporated 
within the framework. This included a biological 
plausibility (or ‘rationale’) criterion to justify, using 
molecular biological or pharmacological principles, the 
plausibility of treatment effect modification (or inter-
action) between the biomarker itself and the drug, or 
alternatively between the drug and another factor for 
which the biomarker is a proxy. A criterion was also 
included to ascertain whether there is any other vali-
dated biomarker which predicts variation in the com-
parative treatment effect (between using the drug and 
not using the drug) (Additional File 1 of [42]).
In addition, information was requested to ascertain 
whether the proposed genetic biomarker is a prognos-
tic factor or a treatment effect modifier and to deter-
mine the strength of any treatment effect modification 
(Additional File 1 and Additional File 3 of [42]).
The end product in 2010 was 79 information 
requests that have been incorporated into Government 
guidance for applicants seeking reimbursement of 
companion tests and drugs (Additional File 1 of [42]). 
The optimal study designs needed to address some of 
the 79 items and methods for presenting information 
and reducing bias were also outlined, often with refer-
ence to current methodological norms. Key informa-
tion requested as part of this evaluation framework is 
outlined in Figure 2, as it relates to a simple decision 
analytic model.
One of the advantages of the adaption of LEA to 
pharmacogenetic applications as described in Figure 2, 
is that the clinical evidence is systematically acquired 
and critically appraised for internal and external valid-
ity. This occurs prior to use as inputs and transition 
probabilities in the decision analytic modeling under-
pinning the economic evaluation [44]. Cost–effective-
ness estimates are therefore likely to be more realistic 
and arguably less biased and sensitivity analyses can 
be used to vary key clinical (e.g., harms from inappro-
priate treatment) and cost inputs over which there is 
uncertainty.
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International experience
The method used by the Expert Working Group of 
EGAPP when evaluating genetic tests – including 
pharmacogenetics [45–48] - and developing practice 
recommendations, involves the synthesis of a chain of 
evidence, along with consideration of ACCE model 
criteria [12,27]. As of February 2014, EGAPP had rec-
ommended 36 tier 1 pharmacogenetic interventions – 
30 of which are used to guide cancer treatment - with 
a base of synthesized evidence supporting implementa-
tion into clinical practice [72]. In 2013, the Working 
Group started investigating basic modeling techniques 
to deal with the lack of available evidence on genetic 
tests [12]. The Working Group supports the need for 
additional approaches and methods for evidence gen-
eration and innovative modeling strategies. They also 
recognize that basing recommendations on evidence 
from poorer quality studies (risk of bias) will require 
accepting a higher risk of providing no net health 
benefit or introducing patient harms. As such, consis-
tent with the Australian approach, they indicate that 
there needs to be a careful consideration of the risk of 
harm balanced with the opportunity for benefit when 
considering a genetic test, and to develop a plan for 
addressing evidence gaps [12].
The evaluation of pharmacogenetics in Europe is 
lagging a little behind other major developed health 
systems and part of the reason relates to structural 
impediments. In the United Kingdom, the National 
Institute of Health and Care Excellence (NICE) is 
making some headway in evaluating products that 
have dissimilar regulatory evidence requirements, such 
as CE-marked and in-house laboratory tests, as well 
as pharmaceuticals. Other European countries, how-
ever, often have completely unlinked processes, which 
makes it particularly difficult to evaluate both the test 
and the drug in a coherent manner [49]. Health tech-
nology assessments conducted in Europe again exem-
plify the learning curve associated with identifying 
evidence that can properly populate economic models 
to inform policy makers of the cost–effectiveness of 
pharmacogenetic interventions [50].
To date, NICE has completed one pharmacogenetic 
test appraisal under their new diagnostic assessment 
program [51], with a further four underway. Although 
several pharmacogenetic interventions have been 
evaluated using the NICE Technology Appraisal pro-
cess, the required evidence base mainly pertains to the 
clinical effectiveness and cost–effectiveness of the drug 
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Figure 2. Using the results from linked evidence as inputs in a simple decision analytic model to estimate the comparative costs and 
effectiveness of a pharmacogenetic intervention. 
*Drug B is usual care (e.g., one or more drugs) but a scenario could be tested whereby this could be Drug A (the proposed 
pharmacogenetic drug) without the use of a companion genetic test 
Note: Inputs used for different pathways in the model can be extracted from different types of studies (preferably with a low risk of 
bias) but there needs to be clinically sensible transferability between the linkages.
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ing whether the genetic test is effective in identifying 
the eligible patient population [50]. This means that 
until recently there has been minimal scrutiny as to 
whether the drug is being appropriately targeted and/
or inappropriately replacing effective treatments as a 
consequence of incorrect test results.
The NICE diagnostic test assessment program rec-
ognizes the utility of the linked evidence approach 
when modeling the effects of testing. The methods 
manual states “If data on the final patient outcomes 
of a diagnostic technology are not available, it may be 
necessary to combine the evidence from different parts 
of the care pathway. In this case the linkages between 
diagnosis, treatment and final outcomes need to be 
specified, and relevant data about those linkages needs 
to be obtained and reviewed. Data about test accuracy 
and the nature of the care pathway and its outcomes 
can be used to create an assessment comparing the 
effect of different testing approaches.” [5]
The experience in Australia of assessing companion 
test-drug combinations for reimbursement decisions 
has accelerated since the introduction of the co-depen-
dent technology evaluation framework. Apart from the 
five pharmacogenetic interventions that were used as 
case studies for the development of the framework in 
late 2010, there have been a further nine companion 
test-drug evaluations conducted since the evaluation 
framework was finalized. Five of these interventions 
were reimbursed, two were rejected and two have been 
deferred (as of March 2014, see Table 2). The evalua-
tion framework appears to be working well in terms of 
the technical requirements being met and evaluated in 
a fairly timely way. Given the lack of available direct 
evidence, many of the applications have had to provide 
linked evidence to address many of the 79 information 
requests [42]. Areas of uncertainty are made clear and 
the use of specific inputs in the models can be critically 
appraised. This has allowed Government to negotiate 
reduced prices as a consequence of the uncertainties 
identified [52–54]. It has also allowed subsidized mar-
ket access for products that would not previously have 
been considered as having an acceptable evidence base 
because of the lack of direct evidence [42], and perhaps 
rejected for public funding.
Table 2. Pharmacogenetic interventions submitted for a reimbursement decision in Australia after introduction of 
the co-dependent evaluation framework.
Condition Genetic test/
biomarker
Drug Current status (March 2014)




Dabrafenib Funding of test and drug recommended. Prospective data 
collection on test utilization to be undertaken to inform the risk-
share arrangement [52,59]
HIV infection Genotype 
test for HIV 
tropism
Maraviroc Funding of test rejected on basis of insufficient evidence that test 
adequately distinguishes between HIV-infected individuals who 
should and should not receive Maraviroc [60,61]
Gastric cancer HER2 gene 
amplification
Trastuzumab Recommendation deferred as further consolidation of information 
required between committees assessing test and drug [62,63]




Gefitinib Funding of test and drug recommended [53,64]




Vemurafenib Not considered cost-effective. Recommendation deferred pending 
further negotiation with the sponsor. Sponsor indicated it is 
unlikely to re-submit an application [65,66]




Erlotinib Funding of test and drug recommended [54,67]
Breast cancer HER2 IHC test Neoadjuvant 
trastuzumab
Funding of test and drug recommended [68,69]
NSCLC ALK test Crizotinib Recommendation deferred. Acceptable comparative effectiveness. 
Unacceptable cost-effectiveness and so negotiation with sponsor 




KRAS testing Panitumumab Funding of drug recommended. Test currently listed but additional 
information being sought with regard to role of wider RAS 
testing  [71]
IHC: Immunohistochemistry; NSCLC: non-small cell lung cancer.
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There have, however, been lengthy delays in some 
instances because of the need to coordinate policy pro-
cesses – perhaps similar to the European situation. As 
Australia has independent committees evaluating each 
of the test and drug [55], there have been several defer-
rals in order to seek advice from the other Commit-
tee and so there have been delays before coordinated 
advice could be provided to Government.
Limitations of LEA
One of the limitations of LEA is finding evidence to 
support all areas of the linkage. This does not mean 
that the companion test and drug are not beneficial, 
only that there is insufficient evidence to make a deter-
mination either way. The main area of difficulty is 
identifying evidence of the likely treatment effect of 
the co-dependent pharmaceutical in patients without 
the biomarker or in an untested population.
Some researchers suggest that in the biomarker 
development phase, once a specific treatment is estab-
lished, it is unethical to randomize patients to a control 
arm of no therapy until there are sufficient data on the 
biomarker’s clinical validity [56]. Industry researchers 
have also suggested that if a pharmaceutical has been 
developed to target a particular biomarker it would be 
unethical to randomize patients without the biomarker 
to receive that pharmaceutical. Studies are less likely to 
be mounted when there is a risk of harm.
Either way, when there is a lack of information to 
support those aspects of the linkage, modeling can be 
undertaken to determine whether the conservative 
assumptions of clinical benefit/harm that necessarily 
need to be made are likely to have an impact on the 
overall clinical and cost–effectiveness of the pharma-
cogenetic intervention. However, modeling cannot 
substitute for good trial data and trials should be per-
formed when there is equipoise regarding likely benefits 
and harms; such that even if a pharmaceutical has been 
developed to address a particular biomarker it needs 
to be confirmed through robust trial evidence that the 
biomarker is relevant. There have been instances in the 
past where researchers have wrongly attributed a clini-
cal benefit or harm to an interaction between a genetic 
biomarker and drug [27,56].
An example of the limitations associated with 
LEA can be drawn from the first pharmacogenetic 
test evaluation conducted by an external assessment 
group commissioned by NICE under the diagnostic 
assessment program [51]. Three modeling methods 
were provided to estimate the cost–effectiveness of 
different EGFR tyrosine kinase tests in adults with 
locally advanced or metastatic lung cancer experi-
ence. These included: 1) a ‘comparative effectiveness’ 
analysis which only used direct evidence of testing on 
final health outcomes; 2) a ‘linked evidence’ analysis 
which included evidence of test accuracy for predict-
ing response to tyrosine kinase inhibitors, accord-
ing to EGFR mutation status, and the clinical effect 
was estimated from other trials; 3) and an ‘assump-
tion of equal prognostic value’ analysis when no data 
were available on either the comparative effectiveness 
or the accuracy of EGFR mutation tests for predict-
ing response to tyrosine kinase inhibitors. The incre-
mental cost effectiveness ratio (ICER) produced using 
either the direct or linked evidence approaches were 
very similar (the ICER for the prognostic value analy-
sis could not be calculated). However, the test accuracy 
estimates used in the linked evidence model were con-
sidered unreliable as they were sampled from different 
populations, using different test methods and different 
definitions of resistance mutations. As a consequence 
of this, the cost–effectiveness analysis was not consid-
ered robust by NICE. Despite these uncertainties, a 
decision was made to recommend EGFR testing with 
Sanger sequencing based methods, the Cobas EGFR 
mutation test and the TheraScreen EGFR PCR kit [51].
This example highlights how, even using linkage 
methods to extract the most out of the pharmaco-
genetic data available, it is critical to ensure that the 
evidence used to derive inputs for modeling is inter-
nally consistent, clinically meaningful and transfer-
able across the linkages ie similar populations, tests, 
biomarker definitions and outcome criteria are used.
Future perspective
Despite the difficulties associated with the evaluation 
of a test to identify a single genetic biomarker that 
could guide treatment with a single pharmaceutical 
(sometimes over a background of usual care), pharma-
cogenetics is actually a simple example of a personal-
ized (or stratified) medicine. Reimbursement consider-
ation of the use of genome testing paired with targeted 
prophylactic and symptomatic treatment raises further 
complexities – technical, legal, ethical and social.
The genome is the entirety of an organism’s heredi-
tary information. The introduction of DNA microar-
ray platforms and projects like IT Future Of Medi-
cine (ITFOM) [73] – a consortium of partners whose 
role it is to construct computational models of the 
molecular and anatomical biological processes that 
occur in every human – means that integrated maps of 
human genomes across diverse populations are being 
developed and can be used to predict and validate 
genome wide association studies [57]. In the future, 
genomic regions associated with human disease will 
be able to be isolated and both prophylactic and symp-
tomatic treatments will be able to be targeted to each 
individual’s genomic profile [33].
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Proponents of this type of research have indicated 
that in these circumstances randomized controlled tri-
als will become obsolete and that n-of-1 trials would 
be the only possible alternative for determining the 
clinical benefits and harms of individualized therapies. 
However, it is unlikely that payers would subsidize 
population-based testing and treatments solely on the 
basis of n-of-1 studies [58]. An alternative could be the 
Executive Summary
Tests are not perfect
•	 Inaccurate tests can lead to delayed, inappropriate or harmful treatment.
•	 Trial evidence of the direct impact of medical tests on the health outcomes of patients is scarce.
The ‘Linked Evidence Approach’ (LEA)
•	 The ‘linked evidence approach’ (LEA) is an integrative framework, developed in Australia, that narratively links 
evidence addressing key elements of the test-treatment pathway. The framework used to link the disparate 
pieces of evidence is a hypothetical randomized controlled trial designed to determine the diagnostic 
effectiveness of the new test. As direct trial evidence is often absent, this linkage approach maximizes the 
available information for policy makers so that the likely impact of the new test on patient health outcomes 
can be determined.
•	 The findings from these evidence linkages can be used as inputs in decision analytic modeling to predict 
whether the new test provides good value for money when compared to existing diagnostic approaches.
•	 LEA was informed by methods pioneered by the United States Preventive Services Task Force (USPSTF) and the 
efficacy criteria proposed by Fryback and Thornbury (1991).
Genetic testing & methods of evaluation
•	 The Office of Public Health Genomics in the USA has produced two key programs for the evaluation of 
emerging genetic tests – the ACCE Model Project and the Evaluation of Genomic Applications in Practice and 
Prevention (EGAPP) initiative.
•	 Pharmacogenetic interventions involving a companion genetic test and tailored drug treatment have been 
emerging over the last decade and this has created challenges for existing technology approval mechanisms.
Adapting LEA to pharmacogenetic interventions for policy decisions
•	 Pharmacogenetic interventions often have a poorer evidence base than other testing interventions. However, 
research suggests that the strength of evidence available to support the clinical benefits/harms of these 
interventions is the key predictor of positive reimbursement decisions.
•	 In order to address the deficiencies in the typical evidence base for pharmacogenetic interventions, an 
evaluation framework to inform reimbursement decisions was developed using an adaptation of LEA.
The co-dependent technology evaluation framework
•	 The approach uses the hypothetical framework of a double randomized controlled trial as a template for 
determining what information elements are needed for the evaluation. Information is also elicited on the 
biological plausibility of the genetic biomarker, as well as whether the biomarker is a prognostic factor or an 
effect modifier for the accompanying drug therapy. All of this information is linked narratively and then the 
findings are integrated using decision analytic modeling.
•	 The framework includes 79 information requests and these have been incorporated into Government 
guidance for applicants seeking reimbursement of these companion tests and drugs.
International experience
•	 Methods of linking evidence to inform test reimbursement decisions is gaining momentum but the largest 
application to pharmacogenetic interventions is in Australia. Since 2011, nine pharmacogenetic test-drug 
evaluations have been conducted. Five of these personalized medicines were publicly funded, two were 
rejected and two have been deferred. To date, the National Institute of Health and Care Excellence (NICE), UK, 
has evaluated one pharmacogenetic intervention but has a further four underway.
Limitations of LEA
•	 The main limitation of LEA is finding evidence to support all areas of the linkage and to ensure that there is 
transferability of populations, genetic tests, biomarker definitions and outcome criteria between each linked 
piece of evidence, particularly when used in economic modeling.
Future perspective
•	 Regulatory and reimbursement consideration of the use of genome testing to guide targeted prophylactic 
and symptomatic treatments raises further complexities – technical, legal, ethical and social.
•	 The suggestion that the current evidence-based paradigm is too inflexible to address individualized medicine 
– through genomics – is premature. Complementary assessment methods can be used, including the use of 
LEA to inform genomic prediction models and then the validation of genomic prediction models to guide 
therapies using standard empirical methods.
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use of complementary evaluation processes. Linked 
evidence approaches addressing stratified personal-
ized medicines (pharmacogenetics) could be used to 
inform policy making and at the same time inform 
the prediction models that have been developed for 
individualized medicines using synthesised n-of-1 
data. The rigorous approaches used to inform reim-
bursement decisions would mean that there is some 
assurance that the genetic association underpinning a 
stratified personalized medicine is valid. The individu-
alized risk prediction models could then be assessed 
in studies that compare treatment/prophylaxis guided 
by ITFOM (or other) genome risk prediction models 
versus treatment guided by clinical judgment (or a 
previous version of a risk prediction model). Random-
ized controlled trials could be used to assess short term 
benefits/harms of the two types of treatment targeting 
models and/or prospective cohort studies, registries or 
comparative effectiveness research [56] could be used 
to assess long-term benefits/harms. The risk predic-
tion models would likely need review and re-specifi-
cation on an ongoing basis as new developments and 
understandings occur in the personalized medicine 
evidence base.
Conclusion
Momentum is gaining in the use of linked evidence 
approaches to identify relevant data on pharmacoge-
netic interventions and to synthesize the findings in 
a robust and yet flexible manner for reimbursement 
decisions. However, the approach should be used and 
appraised cautiously as the body of accumulated evi-
dence needs to maintain internal clinical coherence. 
The approach is meant to be a proxy for an ideal trial 
design, it is not meant to be a ‘Frankenstein creation’ 
for incorporating disparate or biased pieces of evi-
dence. The approach, if used well, can explicate the 
patient risks and benefits from pharmacogenetic inter-
ventions, enable value for money determinations to be 
made, and assist policy makers to formulate informed 
reimbursement decisions.
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